CYGX
- Thread starter Captain Crunch
- Start date
Nothing new to report except the PPS seems to be heading in the direction we want. The chart watchers at IHUB are saying things are looking good as far as TA goes.
Good Luck
Good Luck
TJ, I was out of town last week, and that was definetely nice to come home to yesterday. I know I have stated in the past that I think there are some posters on the IHUB board who are in the know, and they have been very silent the last couple of weeks after dropping a few hints that the holiday season will be one to remember. I realize not many of their predicitions have panned out, but I'm hoping that the reason for the company being quiet lately is that they have been working on some sort of financing deal with a big pharma. Strictly a guess though. I guess if this is the ground breaking technology I hope it is, I'm sure that it is taking an extraordinary amount of time to get all of the pieces together.
Not sure about the status of Dr. Chen at that vaccine conference, but will post anything of importance when I hear.
Good Luck
Not sure about the status of Dr. Chen at that vaccine conference, but will post anything of importance when I hear.
Good Luck
Captain, the last I remember being posted on the CYGX board had a reference to Dr. Chen NOT presenting at that conference. As I recall. From feeble memory, only.
Man, the little runup has been nice, they just have to show something solid to make an impact. This one could fly if just one of the irons gets hot. It's just excruciating having so much money tied up waiting on it to hit.
Man, the little runup has been nice, they just have to show something solid to make an impact. This one could fly if just one of the irons gets hot. It's just excruciating having so much money tied up waiting on it to hit.
Chadman, I find it interesting that we have had this nice little run with no news. Trying to read between the lines would make one think that something positive is in the works.
Also, why would Dr. Chen not be a speaker at the vaccine convention. I refuse to believe that the people running this company would be so stupid not to have him speak unless there was a good explanation.
Strictly just a hunch, but I'm betting there is something in the works with a big pharma that we hopefully will be finding out about soon. Guess we will have to wait a little bit longer to find out.
Good Luck
Also, why would Dr. Chen not be a speaker at the vaccine convention. I refuse to believe that the people running this company would be so stupid not to have him speak unless there was a good explanation.
Strictly just a hunch, but I'm betting there is something in the works with a big pharma that we hopefully will be finding out about soon. Guess we will have to wait a little bit longer to find out.
Good Luck
It looks like these "insiders" might know what they are talking about this time. We have had a nice little run over the last three weeks with no news and with the volume spike today, might be in for some good news soon. :mj09:
nice to hear from you captain, i was excited when i saw it closed at .705 today. Hopefully we hear something great soon, thanks again for the updates!
Hoops, glad to hear you are still in. Can't help but think something good is in the works. The company hasn't issued a NR since August 29 and we have had this nice little run.
I hated watching this thing bounce around as it did since I first posted about this company. I know some people don't have much patience, especially when the PPS goes down, but I have always liked the long term potential here and decided to ride it out to the end, whenever that may be. Hopefully this is our winning lottery ticket.
Good Luck and will post any news as soon as I see it. Hopefully it will be on the national news and I won't have to worry about posting it.
I hated watching this thing bounce around as it did since I first posted about this company. I know some people don't have much patience, especially when the PPS goes down, but I have always liked the long term potential here and decided to ride it out to the end, whenever that may be. Hopefully this is our winning lottery ticket.
Good Luck and will post any news as soon as I see it. Hopefully it will be on the national news and I won't have to worry about posting it.
if this hits the national news you'll be getting a nice thank you gift for this info. i'm not missing out on anything, i'm here for the long-run and hopefully a nice boost in stock price.
vanbasten said:
Not sure what your asking VB, but considering we have seen this nice run on no news, I would sit and wait and see what transpires. If you have read all four pages of this thread, then I'm sure you know how I feel about this company and the possibility of some huge gains in the PPS. I'm sure we are gonna find out one way or another why the increase in volume lately, but if and when news hits, think about the potential of the long term before you sell all of your shares. I hate trying to tell people what to do with their money, but if some of their projects they are working on are the real deal, this won't be a penny stock for long IMO.
Good Luck
Captain Crunch said:
sorry to be vague in my post. purchased it back in september based on this post. keep it on my desktop along with other holdings and watch it. most others i have i know about. just look to this post for my info on CYGX.
the answer you gave me above are enough for me to continue to hold, and no worries on what the end result is. if i didn't like what i see, i wouldn't have jumped in.
thank you.
too late too get in @ 74 Was looking at a modest investment, maybe 1 or 2k shares or so. I was quoted .74 this morning.
Last edited:
Not sure how to explain this in layman's terms, but from the looks of the volume this morning, it looks like some people like the sound of it. Hopefully more good news to come.
Good Luck
NEWS ,NEWS ,NEWS
December 19, 2005 - 5:04 PM EST
CytoGenix and Aldevron Announce Positive Results of synDNA(TM) Hepatitis Vaccine Study
CytoGenix, Inc. (OTCBB:CYGX) and Aldevron, LLC announced positive results of a pilot study using CytoGenix synDNA(TM) as the active ingredient in a Hepatitis B vaccine, demonstrating that it is highly effective in generating an immune response.
DNA vaccines are comprised of genes that confer immunologic protection by producing antigens without the need to expose the body to pathogenic organisms. For this study, CytoGenix scientists prepared a synthetic DNA vaccine derived from a plasmid provided by Aldevron that produces a Hepatitis B viral surface antigen. Aldevron's scientists tested CytoGenix synDNA(TM) vaccine's activity in a rabbit model using Aldevron's proprietary Genetic Immunization and Antibody (GIA(TM)) technology.
Aldevron scientists compared levels of gene-specific serum immunoglobulin produced by the synDNA(TM) vaccine to its traditional plasmid DNA vaccine. The synDNA(TM) vaccine generated immunoglobulin levels in the test animals up to five times greater than a comparable plasmid DNA vaccine produced by bacterial fermentation.
Frank Vazquez, CytoGenix, Inc.'s Executive Vice President and COO, commented, "These results are very important because they confirm the effectiveness of synDNA(TM) that we have seen in other animal studies of DNA vaccines. It is clear that our synDNA(TM) process produces bio-active DNA. This latest result is a major step forward in our efforts to accelerate CytoGenix' Rapid Response Vaccine Development Program against H5N1 avian flu, smallpox and other infectious disease targets."
Michael Chambers, Aldevron President and CEO, stated, "Aldevron has supported the DNA vaccine field for the past seven years by providing quality DNA, antibody and protein products as well as by sponsoring scientific forums and maintaining the DNAvaccine.com web site. The synDNA(TM) process is potentially a big step forward in the DNA vaccine and gene medicine fields. We look forward to expanding Aldevron-CytoGenix scientific and business collaboration."
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
About Aldevron: With facilities in the United States and Europe, Aldevron offers products and services to DNA vaccine and gene therapy scientists. These include contract bio-manufacturing, genetic immunization and antibody production, and a complete line of gene therapy plasmids. More information can be found at http://www.aldevron.com.
Good Luck
NEWS ,NEWS ,NEWS
December 19, 2005 - 5:04 PM EST
CytoGenix and Aldevron Announce Positive Results of synDNA(TM) Hepatitis Vaccine Study
CytoGenix, Inc. (OTCBB:CYGX) and Aldevron, LLC announced positive results of a pilot study using CytoGenix synDNA(TM) as the active ingredient in a Hepatitis B vaccine, demonstrating that it is highly effective in generating an immune response.
DNA vaccines are comprised of genes that confer immunologic protection by producing antigens without the need to expose the body to pathogenic organisms. For this study, CytoGenix scientists prepared a synthetic DNA vaccine derived from a plasmid provided by Aldevron that produces a Hepatitis B viral surface antigen. Aldevron's scientists tested CytoGenix synDNA(TM) vaccine's activity in a rabbit model using Aldevron's proprietary Genetic Immunization and Antibody (GIA(TM)) technology.
Aldevron scientists compared levels of gene-specific serum immunoglobulin produced by the synDNA(TM) vaccine to its traditional plasmid DNA vaccine. The synDNA(TM) vaccine generated immunoglobulin levels in the test animals up to five times greater than a comparable plasmid DNA vaccine produced by bacterial fermentation.
Frank Vazquez, CytoGenix, Inc.'s Executive Vice President and COO, commented, "These results are very important because they confirm the effectiveness of synDNA(TM) that we have seen in other animal studies of DNA vaccines. It is clear that our synDNA(TM) process produces bio-active DNA. This latest result is a major step forward in our efforts to accelerate CytoGenix' Rapid Response Vaccine Development Program against H5N1 avian flu, smallpox and other infectious disease targets."
Michael Chambers, Aldevron President and CEO, stated, "Aldevron has supported the DNA vaccine field for the past seven years by providing quality DNA, antibody and protein products as well as by sponsoring scientific forums and maintaining the DNAvaccine.com web site. The synDNA(TM) process is potentially a big step forward in the DNA vaccine and gene medicine fields. We look forward to expanding Aldevron-CytoGenix scientific and business collaboration."
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
About Aldevron: With facilities in the United States and Europe, Aldevron offers products and services to DNA vaccine and gene therapy scientists. These include contract bio-manufacturing, genetic immunization and antibody production, and a complete line of gene therapy plasmids. More information can be found at http://www.aldevron.com.
More news:
CytoGenix, Inc. CYGX announced today that a suit brought by the US Virgin Island firm of Phanuel Pursuits, L.L.C. against CytoGenix, Inc., the officers and one director has been vacated and dismissed by the District Court of Harris County, Texas 334th Judicial District.
The Court granted summary judgment motions in favor of CytoGenix and against Phanuel Pursuit's cause of action. The Court also found no evidence to support Phanuel Pursuit's allegations and dismissed claims against the individual officers and director. Phanuel Pursuits was demanding damages in excess of $500 million claiming breach of option contracts calling for Phanuel Pursuits to obtain regulatory approval for the distribution of CytoGenix' herpes product in India and in China.
Dr. Malcolm Skolnick, CytoGenix, Inc.'s President and CEO, commented, "We are pleased to put this suit behind us. We welcome the opportunity to devote our full attention to advancing our science, developing our products and running our business."
CytoGenix, Inc. CYGX announced today that a suit brought by the US Virgin Island firm of Phanuel Pursuits, L.L.C. against CytoGenix, Inc., the officers and one director has been vacated and dismissed by the District Court of Harris County, Texas 334th Judicial District.
The Court granted summary judgment motions in favor of CytoGenix and against Phanuel Pursuit's cause of action. The Court also found no evidence to support Phanuel Pursuit's allegations and dismissed claims against the individual officers and director. Phanuel Pursuits was demanding damages in excess of $500 million claiming breach of option contracts calling for Phanuel Pursuits to obtain regulatory approval for the distribution of CytoGenix' herpes product in India and in China.
Dr. Malcolm Skolnick, CytoGenix, Inc.'s President and CEO, commented, "We are pleased to put this suit behind us. We welcome the opportunity to devote our full attention to advancing our science, developing our products and running our business."
Captain
You have had this stock for some time and I bought in awhile ago myself. I'm showing an excellent profit right now and sold of enough to cover my original investment. What are you looking for a target price before you sell?
Thanks for this great tip, it has been a fun stock to watch.
msm
You have had this stock for some time and I bought in awhile ago myself. I'm showing an excellent profit right now and sold of enough to cover my original investment. What are you looking for a target price before you sell?
Thanks for this great tip, it has been a fun stock to watch.
msm
